BMO 'Incrementally Positive' on Valeant (VRX) Following Conf. Call; Still See N-T Headline Risk Affecting Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS
November 11, 2015 9:44 AM EST(Updated - November 11, 2015 9:49 AM EST)
(correction: price target is $255)
UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More
Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% Loss
November 10, 2015 2:01 PM ESTEmbattled Valeant Pharma (NYSE: VRX) has gone solidly positive territory mid-day after trading down as much as 7.5% earlier. Shares last traded at $85.63, up 0.3%. Upside is related to... More
Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'
November 10, 2015 9:25 AM ESTWith its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.
CEO Michael Pearson also the company "is going to survive" and... More
Drugmaker Valeant to feel sting of closing controversial pharmacy
November 10, 2015 8:26 AM ESTBy Euan Rocha and Rod Nickel
TORONTO/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.
As of last week, Philidor Rx Services has stopped handling insurance claims for drugs and it will cease operations by the end of January, Valeant Chief Executive Officer Mike Pearson told investors and analysts on a conference call on Tuesday.
The call, however,... More
Valeant Pharma (VRX) on Watch as Call Starts
November 10, 2015 8:02 AM ESTValeant Pharma (NYSE: VRX) is on watch as the company's conference call is starting now.
The dial-in number to participate on this call is (877) 876-8393 confirmation code 78262163. International callers should dial (973) 200-3961, confirmation code 78262163. A replay will be available approximately two hours... More
